Summary
F/M Emerald Life Sciences Innovation ETF is an ETF - a fund traded on an exchange like a stock - run by Emerald. Positions inside: 40. The ten largest make up 54% of the fund.
- Yearly costs
- 0.79%
- Fund size
- $110.0M
- Positions
- 40
- Running since
- 2024
What speaks for it
Nothing stands out in its favour.
What to watch
- The ten largest positions make up 54% of the fund, so its result rests on a few names.
- 93% of the fund is in one country (United States).
- Costs of 0.79% a year are above the middle of comparable funds (0.44%).
- A young fund: it has been running only since 2024.
- It trades little: only about $168.0K changes hands a day.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- -3.9%
- 3 months
- -6.3%
- This year
- +16%
- 1 year
- +39%
- Avg. market cap
- $6.45B
- P/E
- -
- Forward P/E
- -
- P/S
- 5.9x
- P/B
- 4.7x
- P/FCF
- -
- EV/EBITDA
- -
- Dividend yield
- 0.00%
- ROIC
- -21.0%
- ROE
- -51.9%
- Gross margin
- 72.2%
- Operating margin
- -426.4%
- Net margin
- -178.0%
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 0.94
Weighted average of the 36 largest companies, which make up 99% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Concentrated- 1 COCorcept Therapeutics CORT 7.5%
- 2 LILivaNova LIVN 7.4%
- 3 TVTravere Therapeutics, Inc. TVTX 6.3%
- 4 COCogent Biosciences, Inc. COGT 6.3%
- 5 GHGuardant Health GH 5.4%
- 6 SYSpyre Therapeutics, Inc. SYRE 5.2%
- 7 BLBillionToOne, Inc. BLLN 4.8%
- 8 REReplimune Group, Inc. REPL 4.0%
- 9 MAVeradermics, Incorporated MANE 3.6%
- 10 MIMirum Pharmaceuticals, Inc. MIRM 3.6%
Positions in the fund: 40. The ten largest make up 54% of it.
Composition as of Oct 19, 2026.
Where is it spread?
One countryBy country
- United States 93%
- United Kingdom 7.4%
By company size
- Large cap 17%
- Mid cap 64%
- Small cap 18%
- Micro cap 0.5%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest country: United States (93%). Largest size group: Mid cap (64%).
What does it cost me?
Expensive- A year from $10,000
- $79.00
- Over 20 years
- $3,720
From every $10,000 invested the fund takes $79.00 a year. You do not pay it separately - it is taken out of the fund's value. Over 20 years at 5% yearly growth that adds up to about $3,720.
How has it done?
Growing over the long run- Over the last year
- +39%
- Deepest drop
- -30%
- Yearly volatility
- 28%
Growth over the last year: 39%. Deepest drop in these years: 30% below the earlier high.
Does it pay dividends?
We have no record of payments from this fund.
Is it easy to buy and sell?
It trades little- Traded a day
- $168.0K
- Shares a day
- 3.9K
On an average day about $168.0K of the fund changes hands.
How expensive are the companies inside?
Rather expensive- Average Bulios Score
- 42 out of 100
Weight by Bulios Fair Price
- Undervalued 14%
- Fairly valued 1.6%
- Overvalued 85%
By Fair Price, 85% of the rated weight comes out as overvalued.
Counted from its largest companies (36), which make up 99% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Similar funds
Funds that hold much of the same. The overlap says how much of their weight they share with this fund.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
SP SPIT F/m Emerald Special Situations ETF | United States | 0.89% | $31.1M | +5.4% | - | 21% |